DIVENSTITURES, LICENSING AND OTHER ARRANGEMENTS - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 28, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Licensing Arrangements [Line Items]
Proceeds from divestiture of businesses, net of cash divested		$ 220	$ 397
Divestiture gain		0	211
Nimbus Therapuetics TYK2 Inhibitor
Licensing Arrangements [Line Items]
Proceeds from legal settlements		400		$ 40
Contingent sales-based milestones	$ 2,000
Other (income)/expense		400
Immatics
Licensing Arrangements [Line Items]
Upfront payments			150
Contingent and regulatory milestone payments			770
Dragonfly
Licensing Arrangements [Line Items]
Upfront payments			175
Nimbus Therapeutics
Licensing Arrangements [Line Items]
Upfront payments	$ 4,000
Nimbus Therapeutics | Nimbus Therapuetics TYK2 Inhibitor
Licensing Arrangements [Line Items]
Change in control proceeds				10.00%
Percentage of ownership acquired	100.00%
Mature products and other
Licensing Arrangements [Line Items]
Proceeds from divestiture of businesses, net of cash divested		4	225
Divestiture gain		$ 0	211
Mature products and other | Cheplapharm
Licensing Arrangements [Line Items]
Proceeds from divestiture of businesses, net of cash divested			$ 221